ProfileGDS5678 / 1417166_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 81% 80% 86% 83% 78% 77% 80% 82% 81% 80% 82% 80% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3559178
GSM967853U87-EV human glioblastoma xenograft - Control 25.8374681
GSM967854U87-EV human glioblastoma xenograft - Control 35.6442780
GSM967855U87-EV human glioblastoma xenograft - Control 46.6368986
GSM967856U87-EV human glioblastoma xenograft - Control 56.0557683
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1679878
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1800577
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6466680
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9502282
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8213281
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6004680
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0299882
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.677480
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.738581